SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AKTX

Akari Therapeutics Plc (NASDAQ:AKTX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$7.18+$0.47 (+7.00%)
 
Market cap
$16.5M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 6, 2014
Market Cap$16.48M-60.1%
Revenue (ttm)$0
Net Income-$29.40M-86.4%
EPS-$12.81-2.7%
Shares Out2.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,265
Open$7.00
Previous Close$6.71
Day's Range$6.23 - $7.44
52-Week Range$3.02 - $29.32
Beta1.47
AnalystsBuy
Price Target$24.75(+244.71%)
Earnings DateApr 21, 2027
+5.96% (1D)
No price history available.

About AKTX

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Address
401 East Jackson Street, Tampa, FL, 33602, US
Market Cap
16 million
Employees
6
Industrial Classification
Biotechnology
Financial Health Score
Weak
From AKTX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+7.00%
5 Days
+1.84%
1 Month
-18.04%
6 Months
+39.69%
1 Year
-60.11%

$AKTX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AKTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AKTX's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AKTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New AKTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AKTX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from AKTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.